ALIGOS THERAPEUTICS, INC.

Company

Aligos Therapeutics, Inc.

Filed

February 16, 2021

Accession Number

0000902664-21-001431

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →